Table 2.
Clinical and laboratory effects of MARS therapy
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |||||||
| Parameter | Normal range | Before | After | Before | After | Before | After | Before | After | Before | After |
| Noradrenaline, μg kg-1 min-1 | 0.22 | 0.02 | 0.06 | 0.16 | 0 | 0 | 0.22 | 0.10 | 0.32 | 0.06 | |
| Creatinine | 60–110 μM | 307 | 142 | 132 | 239 | 171 | 234 | 241 | 144 | 164 | 107 |
| Urea | 2.9–7.1 mM | 21 | 13 | 16 | 22 | 1 | 6 | 11 | 29 | 15 | 17 |
| Ammonia | 15–50 μM | 67 | 47 | ||||||||
| HE grade | 4 | 3 | 3 | 1 | 3 | 2 | |||||
| Bilirubin | <25 μM | 161 | 210 | 654 | 528 | 260 | 182 | 484 | 137 | 510 | 326 |
| Bile acids | 0–6 μM | 75 | 75 | 27 | 16 | 202 | 67 | ||||
| AA/β-OH-But | 4.2 | 6.8 | 1.3 | 8 | 4 | 4.5 | |||||
| PDR ICG | >16% min-1 | 4.4 | 5.5 | 4.3 | 5.2 | 4.3 | 5.4 | 5.6 | 5.2 | ||
| Duration of treatment, h | 24, 16 | 15, 13 | 5, 6 | 12, 16, 20 | 6, 6, 6 | ||||||
| Outcome | ICU D/C, died in ward | Died in ICU | ICU D/C, died in ward | D/C home | Died in ICU | ||||||
AA/β-OH-But, ratio of arterial acetoacetate to β-hydroxybutyrate (ketone body); D/C, discharged; HE, hepatic encephalopathy; ICU, intensive care unit; PDR ICG, plasma disappearance rate of indocyanine green (measured after an intravenous dose of 0.5 mg kg-1 body weight with a non-invasive transcutaneous probe [Pulsion Medical System AG, Munich]).